Simulations Plus (SLP)

• Market cap: $601M
• 1 day: 0.27%
• 5 days: 6.67%
• 1 month: -0.40%
• 3 months: -10.12%
• 6 months: -30.39%
• Year to date: 7.20%
• 1 year: -20.57%
• 5 years: -11.64%
• 10 years: 354.71%
• Sector: Information Technology
• Industry: Computer Integrated Systems Design

About: Simulations Plus Inc is engaged in the software industry. It includes two segments. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.

Employees: 247

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

298% more call options, than puts

Call options by funds: $179K | Put options by funds: $45K

39% more repeat investments, than reductions

Existing positions increased: 61 | Existing positions reduced: 44

9% less first-time investments, than exits

New positions opened: 30 | Existing positions closed: 33

3% less funds holding

Funds holding: 175 [Q2] → 169 (-6) [Q3]

5.34% less ownership

Funds ownership: 82.56% [Q2] → 77.21% (-5.34%) [Q3]

38% less capital invested

Capital invested by funds: $802M [Q2] → $495M (-$308M) [Q3]

100% less funds holding in top 10

Funds holding in top 10: 1 [Q2] → 0 (-1) [Q3]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $35 17% upside
• Avg. target: $41 38% upside
• High target: $50 67% upside

3 analyst ratings

• positive: 3 100%
• neutral: 0 0%
• negative: 0 0%

Keybanc Scott Schoenhaus 17% 1-year accuracy 6 / 36 met price target	17% upside $35	Overweight Maintained	8 Jan 2025
Stephens & Co. Jeff Garro 50% 1-year accuracy 3 / 6 met price target	30% upside $39	Overweight Initiated	15 Nov 2024
BTIG David Larsen 44% 1-year accuracy 8 / 18 met price target	67% upside $50	Buy Maintained	24 Oct 2024